Clinical Trial Update: A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and efficacy of intravitreal ONL1204 ophthalmic solution for mac-off rhegmatogenous retinal detachment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhegmatogenous Retinal Detachment - Macula Off

Drugs mentioned

• ONL1204 Ophthalmic Solution

Snippet

Sponsor: ONL Therapeutics | Conditions: Rhegmatogenous Retinal Detachment - Macula Off | Phase 2 | Status: COMPLETED